Anti-CD25 Antibody CDR Optimization for Selective Treg Depletion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-CD25 antibodies exhibit insufficient binding activity, inhibit PBMC activation, and have poor pharmacokinetic performance, limiting their effectiveness in depleting regulatory T cells (Treg) and enhancing anti-tumor responses.
Innovation Solution
Development of a novel anti-CD25 antibody with enhanced binding activity and affinity, specifically designed to target Treg cells while minimizing inhibition of effector T cells and PBMC activation, using a combination of immunization, phage display, and molecular cloning techniques to create antibodies with optimized heavy and light chain sequences.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-CD25 antibodies are used, then Treg cells can be targeted, but binding activity is insufficient and PBMC activation is inhibited
Solution Approach 1:
The patent applies parameter changes by optimizing the antibody's amino acid sequence, specifically modifying the complementarity determining regions (CDRs) to achieve enhanced binding affinity to CD25 while eliminating the harmful side effect of PBMC activation inhibition. The optimized antibody maintains selective Treg targeting without the adverse effects of prior art antibodies.
2Reliability
If existing anti-CD25 antibodies are used, then Treg depletion can be achieved, but pharmacokinetic performance is poor
Solution Approach 1:
The patent improves pharmacokinetic performance by optimizing the antibody's structural parameters, including the constant regions and overall molecular configuration. These parameter optimizations enhance the antibody's stability, half-life, and circulation characteristics in vivo, thereby improving duration of action while maintaining Treg depletion efficacy.
3Reliability
If existing anti-CD25 antibodies are used, then CD25 binding can be achieved, but binding affinity is insufficient
Solution Approach 1:
The patent applies local quality by specifically optimizing the complementarity determining regions (CDRs) of the antibody, which are the local binding sites that directly interact with CD25. By refining the amino acid sequences in these critical local regions (LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, HCDR3), the patent achieves enhanced binding affinity while maintaining overall antibody structure and function.
4Ease of operation
If existing anti-CD25 antibodies are used, then Treg targeting is possible, but effector T cell activation is inhibited
Solution Approach 1:
The patent resolves this contradiction by optimizing the antibody's binding parameters to achieve selective recognition of Treg cells via CD25 while avoiding cross-reactivity with effector T cells. The optimized amino acid sequence in the CDR regions provides enhanced specificity, allowing the antibody to distinguish between Treg and Teff cells based on their differential CD25 expression patterns, thereby eliminating effector T cell inhibition.
Data Source
Figure 1~2B
Figure 2C~3A
Figure 3B~5
AI summary
The present invention provides an antibody binding to CD25 or an antigen-binding fragment thereof and a use thereof for the preparation of a therapeutic cancer drug. The antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region containing a specific complementarity-determining region sequence. The antibody or antigen-binding fragment has one or more of the following advantages: enhanced CD25 protein binding ability, enhanced CD25 protein affinity, enhanced CD25 expressing cell killing ability, weakened PBMC activation inhibition, enhanced in vivo tumor growth inhibition ability, enhanced in vivo tumor killing ability, enhanced ability to reduce the number of Treg cells, or enhanced ability to increase the number of effector T cells.